When was Rybelsus approved? September 20, 2019. That is the date on the agency's letter for NDA 213051, its file for the new drug. Rybelsus was the first GLP-1 receptor agonist available as a tablet. A GLP-1 receptor agonist is a medicine that copies a gut-hormone signal involved in blood sugar and fullness. Until that Friday, every U.S. medicine in the class had to be injected.
When was Rybelsus approved? The dated document
The approval letter for Rybelsus says the application was approved effective September 20, 2019. It covered semaglutide tablets used with diet and exercise to improve blood-sugar control in adults with type 2 diabetes. It did not approve a general weight-loss pill.
The agency's news release that day carried the dateline "Sep 20, 2019, 10:42 ET". Its plain point was bigger than a new brand name: Rybelsus was the first member of this injectable drug class that did not need an injection.
That distinction is why the date still matters. The breakthrough was not discovering semaglutide. It was getting a peptide, a short chain of amino acids that digestion can break apart, through the stomach in a useful tablet.
What the world looked like the day before
Semaglutide was already a medicine, but it came by needle. The agency's Ozempic approval package dates that weekly injection to December 5, 2017. Other GLP-1 medicines on the U.S. market were injectable too.
That was not a minor inconvenience built into one brand. Peptides generally do poorly in the digestive tract: enzymes can break them down, and the stomach lining is hard for a large molecule to cross. An ordinary semaglutide tablet would deliver very little medicine into the bloodstream.
How SNAC made an oral GLP-1 possible
Rybelsus paired semaglutide with SNAC, an absorption enhancer—an added ingredient that helps a drug cross a body barrier. In a 2018 study, researchers found that the tablet was absorbed through cells in the stomach close to where it dissolved. SNAC briefly raised the local pH, protecting semaglutide from digestive enzymes, and helped it pass through those cells (Buckley et al., Science Translational Medicine, 2018).
The PIONEER program then asked whether that delivery system worked in people with type 2 diabetes. PIONEER 1 enrolled 703 adults and followed them for 26 weeks. At the 14 mg study dose, HbA1c—a measure of average blood sugar over roughly three months—fell 1.1 percentage points more than placebo in the analysis that counted everyone as assigned. The placebo-adjusted weight difference was 2.3 kilograms (Aroda et al., Diabetes Care, 2019). Those are trial results, not a forecast for one person.
For a closer look at the tablet and its fasting routine, see how oral semaglutide works. This page stays with the approval record and what followed.
What happened next, year by year
2019. As the approval decision approached, PIONEER 6 supplied the cardiovascular safety evidence. Cardiovascular means heart and blood-vessel health. Among 3,183 adults at high cardiovascular risk, a major event occurred in 3.8% taking oral semaglutide and 4.8% taking placebo over a median 15.9 months. The study met its noninferiority goal, meaning the result stayed within a pre-set safety margin; it was not designed to prove superiority (Husain et al., New England Journal of Medicine, 2019).
2025. On October 17, an agency supplement letter added a cardiovascular-risk indication for high-risk adults with type 2 diabetes to the Rybelsus label. On December 22, the agency approved Wegovy tablets for weight management and cardiovascular-risk reduction under a separate application, NDA 218316. The same molecule now had oral products built for different jobs.
2026. On January 30, the agency approved a supplement that changed the name of Rybelsus formulation R2 to Ozempic tablets at 1.5, 4, and 9 mg. This was a supplemental labeling approval under the existing Rybelsus NDA, not a second original approval of oral semaglutide. On April 1, Foundayo became a separate oral GLP-1 option. It contains orforglipron, a small non-peptide molecule rather than semaglutide; the Foundayo explainer owns that newer drug's story.
As of September 18, 2026, the day this article was written, a peer-reviewed observational study published September 17 compared existing health records rather than assigning treatments. Among adults with type 2 diabetes and atherosclerotic cardiovascular disease, oral semaglutide use was associated with a 17% lower risk of the study's three-part major cardiovascular outcome than other non-insulin glucose-lowering therapies (Tan et al., Diabetes Therapy, 2026). Association is not proof that the medicine caused the difference, but it is a fresh real-world chapter in the record that began in 2019.
What the 2019 approval means now
Rybelsus proved that a peptide GLP-1 could be delivered in a tablet when the formulation solved the absorption problem. It did not make every product called "oral semaglutide" equivalent, and it did not turn compounded semaglutide into Rybelsus. Form, ingredients, label, and the evidence behind a specific product still matter.
Promise's semaglutide product is dispensed as a compounded injectable, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation when clinically appropriate; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request and not everyone qualifies.
Seven years on, September 20 remains the clean dividing line: before it, U.S. GLP-1 treatment meant an injection; after it, the class also had a tablet with a documented way through the stomach.
